Company / R&D per Share
Cartesian Therapeutics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.75
FY2025
5-year range
$0.40 / $13.20
FY2021-FY2025
Trend
-86.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $0.45 to $1.75 over the past 2 years.
Based on SEC 10-K filings.
1.75 in FY2025 with a 5-year CAGR of +25.9%.
Improved from $0.45 to $1.75 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +58.3%
- 5-Year CAGR
- +25.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share decreased 86.7% year-over-year.
- Peak r&d per share was recorded in FY2024.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.75 | -86.7% |
| FY2024 | $13.20 | +2839.5% |
| FY2023 | $0.45 | +1.9% |
| FY2022 | $0.44 | +11.5% |
| FY2021 | $0.40 | -28.4% |
| FY2020 | $0.55 | -72.5% |
| FY2019 | $2.01 | -58.3% |
| FY2016 | $4.82 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026